Cain A. Hayes
Known title: DirectorCIK: 0001834471
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Encompass Health Sets Q3 2026 Earnings Call Date. Encompass Health announced the date for its 2026 third-quarter earnings call. Recent coverage also highlights the company's small-format expansion strategy and potential undervaluation as it builds out its rehabilitation capacity. The stock is currently trading near the lower end of its 52-week range, with an average analyst target of $148.17.
Transaction History
| DOCU | ▲ Buy | Option Exercise | 1,096 | $0 | 9/1/2026 | View on chart |
| EHC | ▲ Buy | Grant | 4 | $0 | 7/15/2026 | View on chart |
| DOCU | ▲ Buy | Option Exercise | 729 | $0 | 5/29/2026 | View on chart |
| EHC | ▲ Buy | Grant | 1,634 | $0 | 5/7/2026 | View on chart |
| EHC | ▲ Buy | Grant | 1 | $0 | 4/15/2026 | View on chart |
| DOCU | ▲ Buy | Option Exercise | 729 | $0 | 2/28/2026 | View on chart |
| EHC | ▲ Buy | Grant | 457 | $0 | 1/30/2026 | View on chart |
| DOCU | ▲ Buy | Option Exercise | 729 | $0 | 11/29/2025 | View on chart |
| DOCU | ▲ Buy | Option Exercise | 729 | $0 | 8/29/2025 | View on chart |
| DOCU | ▲ Buy | Option Exercise | 1,069 | $0 | 5/29/2025 | View on chart |
| DOCU | ▲ Buy | Option Exercise | 1,068 | $0 | 2/28/2025 | View on chart |
| DOCU | ▲ Buy | Option Exercise | 1,068 | $0 | 11/29/2024 | View on chart |
| DOCU | ▲ Buy | Option Exercise | 1,068 | $0 | 8/29/2024 | View on chart |
| DOCU | ▲ Buy | Option Exercise | 998 | $0 | 5/29/2024 | View on chart |
| DOCU | ▲ Buy | Option Exercise | 997 | $0 | 2/29/2024 | View on chart |
| DOCU | ▲ Buy | Option Exercise | 155 | $0 | 12/1/2023 | View on chart |
| DOCU | ▲ Buy | Option Exercise | 997 | $0 | 11/30/2023 | View on chart |
| DOCU | ▲ Buy | Option Exercise | 154 | $0 | 9/1/2023 | View on chart |
| DOCU | ▲ Buy | Option Exercise | 997 | $0 | 8/31/2023 | View on chart |
| DOCU | ▲ Buy | Option Exercise | 155 | $0 | 6/1/2023 | View on chart |
| DOCU | ▲ Buy | Option Exercise | 672 | $0 | 5/31/2023 | View on chart |
| DOCU | ▲ Buy | Option Exercise | 671 | $0 | 3/3/2023 | View on chart |
| DOCU | ▲ Buy | Option Exercise | 154 | $0 | 3/1/2023 | View on chart |
| DOCU | ▲ Buy | Option Exercise | 671 | $0 | 12/3/2022 | View on chart |
| DOCU | ▲ Buy | Option Exercise | 155 | $0 | 12/1/2022 | View on chart |
| DOCU | ▲ Buy | Option Exercise | 671 | $0 | 9/3/2022 | View on chart |
| DOCU | ▲ Buy | Option Exercise | 154 | $0 | 9/1/2022 | View on chart |
| DOCU | ▲ Buy | Option Exercise | 155 | $0 | 6/1/2022 | View on chart |
| DOCU | ▲ Buy | Option Exercise | 154 | $0 | 3/1/2022 | View on chart |
| DOCU | ▲ Buy | Option Exercise | 155 | $0 | 12/1/2021 | View on chart |
| DOCU | ▲ Buy | Grant | 154 | $0 | 9/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
DocuSign Quotation Resumes After Trading Halt
DocuSign shares resumed trading after a brief halt, marking the release of the security for quotation. This event coincides with broader positive momentum in the software sector, where peers like FactSet reported strong earnings and EPAM announced a significant share repurchase. Analysts currently hold an average price target of $69.99 for the stock.
DocuSign Quotation Resumes After Trading Halt. DocuSign shares resumed trading after a brief halt, marking the release of the security for quotation. This event coincides with broader positive momentum in the software sector, where peers like FactSet reported strong earnings and EPAM announced a significant share repurchase. Analysts currently hold an average price target of $69.99 for the stock.